General Information of Drug (ID: DMFZNLH)

Drug Name
BMS-204352 Drug Info
Synonyms
Flindokalner; MaxiPost; BMS-204352; 187523-35-9; Flindokalner [USAN:INN]; UNII-J57O328W4W; (3S)-3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1,3-dihydro-2H-indol-2-one; BMS 204352; J57O328W4W; 2H-Indol-2-one, 3-(5-chloro-2-methoxyphenyl)-3-fluoro-1,3-dihydro-6-(trifluoromethyl)-, (3S)-; Maxipost (TN); (s)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)indolin-2-one; (3S)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1H-indol-2-one; Bms204352; Flindokalner (USAN/INN); AC1Q4JQL; AC1L4WO7
Indication
Disease Entry ICD 11 Status REF
Nerve injury ND56.4 Discontinued in Phase 3 [1]
Cross-matching ID
PubChem CID
214350
CAS Number
CAS 187523-35-9
TTD Drug ID
DMFZNLH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nateglinide DMLK2QH Diabetic complication 5A2Y Approved [3]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [3]
Dronedarone DMA8FS5 Angina pectoris BA40 Approved [4]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [3]
Amifampridine DMK08L3 LambertEaton myasthenic syndrome 8C62 Approved [5]
Minoxidil DMA2Z4F Alopecia ED70 Approved [3]
Pinacidil DMRADYL High blood pressure BA00 Approved [3]
Dalfampridine DMM0PDO Multiple sclerosis 8A40 Approved [6]
Ibutilide DMKXY2R Atrial fibrillation BC81.3 Approved [3]
Diazoxide DML1538 Congenital hyperinsulinism 5A4Y Approved [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Potassium channel unspecific (KC) TT1VOHK NOUNIPROTAC Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2307).
2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
5 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
6 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.